Evaluate Safety, Tolerability and Pharmacokinetics of HLX22 in Patients With Advanced Solid Tumors Overexpressing HER2
Clinical trial NCT03916094 · COMPLETED
Trial details
- NCT number
- NCT03916094
- Sponsor
- Shanghai Henlius Biotech
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-07-31
- Primary completion
- 2021-01-04
- Enrollment
- 11
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.